Pharmaceuticals, Biotechnology and Life Sciences
WATERTOWN, Mass.–(BUSINESS WIRE)–SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and recent business highlights.
“In 2020, we experie…
WATERTOWN, Mass.–(BUSINESS WIRE)–SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and recent business highlights.
“In 2020, we experie…
— Four-year mean follow-up data demonstrate an overall response rate (ORR) of over 80% throughout the follow-up period —
— Randomized, double-blind Phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-posit…
DUBLIN–(BUSINESS WIRE)–The “Neuralgia Treatment Market Size, Share & Trends Analysis Report, By Treatment; By End-Use; By Region, and Segment Forecasts, 2020-2027” report has been added to ResearchAndMarkets.com’s offering.
The global neuralgia …
Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US
DS Biopharma becomes an investor in Nuvothera and takes a Board seat
DUBLIN, Ireland & FORT WORTH, Texas–(BUSINESS WIRE)–DS Biopharma Li…
License with NIH for intellectual property for a clinically-validated, GMP grade feeder cell line to enable robust natural killer (NK) cell expansion
Enhances ONK Therapeutics’ evolving research efforts to scale up and support clinical trials
GALW…
Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US
DS Biopharma becomes an investor in Nuvothera and takes a Board seat
DUBLIN, Ireland & FORT WORTH, Texas–(BUSINESS WIRE)–DS Biopharma Li…
Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US
DS Biopharma becomes an investor in Nuvothera and takes a Board seat
DUBLIN, Ireland & FORT WORTH, Texas–(BUSINESS WIRE)–DS Biopharma Li…
GARCHING, Germany–(BUSINESS WIRE)–ITM AG, a privately held radiopharmaceutical biotech company, announced today that is has signed two strategic agreements with Telix Pharmaceuticals Limited for the global supply of ITM’s highly pure therapeutic radi…
BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating dise…